DarioHealth Stock DRIO · Forecast & Analysis
DarioHealth earns a bullish reading on fundamentals alone, as there are no chart signals for DRIO to lean on. The quarter showed revenue growing again and losses narrowing, though the recovery is gradual rather than a step change.
News situation · 5 items / 30 D
5 of 5 straight from the issuer or regulator
Outlook for DarioHealth
Direction, typical moves and upcoming dates from our own price, news and calendar data, recalculated on every visit. An assessment, not investment advice.
No price statement: there is no price data for this asset. Based on 5 news items.
What drives it
- Q3 revenue of $5.3 million grew year over year and the operating loss fell 15%, so cost cuts are working.
- A New Jersey health plan with 1.5 million covered lives was signed, with revenue starting in 2027.
- The Minnesota Star Tribune became the second Dario Women employer in weeks; revenue is expected from Q1 2027.
- $31.2 million in cash and short-term deposits as of late September back the commercial build-out.
What argues against it
- B2B and B2B2C revenue declined after several of Twill's legacy contracts were not renewed.
- Gross margin slipped to 59% from 60% a year earlier, a small but real setback.
- The company itself flags the adequacy of its existing cash resources as a risk.
- The latest employer win discloses no contract value, member count or revenue amount.
What would change the picture
- Conversion of $13.1 million in contracted and late-stage ARR is guided to lift revenue late 2026 into 2027.
- Whether Dario Women employer wins turn into disclosed contract values and revenue from early 2027.
Both worlds over time
Technical and news signals of the last 90 days on one timeline.
What is being reported about DRIO
Frequently asked questions about DarioHealth
What is behind the bullish reading for DarioHealth right now?
The third quarter showed revenue of $5.3 million growing both year over year and sequentially, while the operating loss fell 15% and expenses dropped 10%. Commercial wins, led by a New Jersey health plan covering 1.5 million lives, add to the case. The catch is that the improvement is gradual: one revenue line is shrinking and gross margin slipped a point.
Why do the Dario Women employer wins matter if no figures were given?
The Minnesota Star Tribune is the second employer signed within weeks, with the program expected live in January 2027 and revenue from the first quarter of 2027. That is real commercial traction for the women's health program, but without a contract value or member count it cannot yet be measured in revenue. It is a signal to watch, not a number to bank on.
What would change the picture for DRIO?
The key test is the guided revenue acceleration from converting $13.1 million in contracted and late-stage ARR around the end of 2026 and into 2027. If that conversion shows up, the bullish case strengthens; if it slips, the gradual-improvement story weakens. Continued B2B declines from the Twill non-renewals and the flagged adequacy of cash reserves are the other things to monitor.
📝 Overview Generated automatically
DRIO has been the subject of 6 signals across 6 articles in the last 365 days. Sentiment skews Neutral (67%).
Breakdown: 2 bullish, 0 bearish, 4 neutral.
Most-cited catalysts: Independent Aon analysis validating $5,077 in annual healthcare cost savings per user (1×), Clinical evidence showing a 23.5% reduction in inpatient discharges for type 2 diabetes patients (1×), Revenue guidance of acceleration at end of 2026 and into 2027 from conversion of $13.1 million contracted and late-stage ARR (1×). Most-cited risk factors: Reliance on third-party actuarial projections for future enterprise sales (1×), Potential for variability in savings across different patient demographics or health plan structures (1×), B2B and B2B2C revenue decreased versus 2025 due to non-renewal of several of Twill's legacy contracts (1×).